DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

Completed

Conditions: Post-essential Thrombocythemia Myelofibrosis
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis

Interventions: Other: Jakavi

First Posted Date: 2021-09-14

Last Posted Date: 2023-09-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1012

Registration Number: NCT05044026

Locations: 🇩🇪
Novartis Investigative Site, Aachen, Germany

Managed Access Programs for LEE011, Ribociclib

Conditions: Breast Cancer

First Posted Date: 2021-09-09

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05038631

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Alpelisib-matching placebo

First Posted Date: 2021-09-09

Last Posted Date: 2025-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 234

Registration Number: NCT05038735

Locations: 🇪🇸
Novartis Investigative Site, Zaragoza, Spain

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Completed

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Drug: Brolucizumab

First Posted Date: 2021-09-08

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9457

Registration Number: NCT05037396

Locations: 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States

Study of Efficacy and Safety of ABO809 in Healthy Participants

Phase 1

Completed

Conditions: Cryptosporidium Infection, Cryptosporidiosis

Interventions: Biological: Cryptosporidium parvum oocysts (ABO809)

First Posted Date: 2021-09-05

Last Posted Date: 2024-10-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05036668

Locations: 🇺🇸
Novartis Investigative Site, Baltimore, Maryland, United States

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded)
Drug: Placebo
Drug: LOU064 (open-label)

First Posted Date: 2021-09-02

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 455

Registration Number: NCT05032157

Locations: 🇺🇸
Cahaba Derm and skin hlth ctr 27, Birmingham, Alabama, United States
🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
Little Rock Allergy and Asthma Clnc, Little Rock, Arkansas, United States

and more 28 locations

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Placebo
Drug: LOU064 25 mg (b.i.d)
Drug: LOU064 25 mg (b.i.d) as a tablet.

First Posted Date: 2021-09-01

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 470

Registration Number: NCT05030311

Locations: 🇹🇷
Novartis Investigative Site, Talas Kayseri, Turkey
🇺🇸
Finlay Medical Research, Greenacres City, Florida, United States

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Phase 3

Active, not recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Inclisiran sodium 300 mg
Drug: Placebo

First Posted Date: 2021-09-01

Last Posted Date: 2025-03-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17004

Registration Number: NCT05030428

Locations: 🇺🇸
Village Medical Village MD S Tx, Houston, Texas, United States
🇺🇸
FMC Science, Lampasas, Texas, United States
🇺🇸
Capitol Cardiology Associates, Lanham, Maryland, United States

and more 264 locations

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Pelacarsen

First Posted Date: 2021-08-30

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT05026996

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Phase 3

Terminated

Conditions: Chronic Inducible Urticaria

Interventions: Drug: Ligelizumab
Other: Placebo

First Posted Date: 2021-08-27

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT05024058

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy